The two-syndrome concept and neuroendocrinology of schizophrenia.
Schizophrenia sometimes remits and sometimes responds to neuroleptic drugs but is a disease that also has a poor long-term outcome, sometimes including behavioral deterioration and intellectual decline. It is proposed that there are two components to pathology: a neurochemical component, perhaps associated with a change in D-2 DA receptors, which is potentially reversible and neuroleptic-responsive and a structural and probably irreversible component, which includes changes in structures bordering the temporal horn of the lateral ventricle and perhaps elsewhere in the brain.
Crow
T J
TJ
Ferrier
I N
IN
Johnstone
E C
EC
D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D001923:Brain Chemistry; D003071:Cognition / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006728:Hormones / Q000502:physiology*; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D011954:Receptors, Dopamine / Q000502:physiology; D017448:Receptors, Dopamine D2; D012559:Schizophrenia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*
D014150:Antipsychotic Agents; D006728:Hormones; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D001058:Apomorphine; D004298:Dopamine